Business Plan Revealed
This is by far the most significant NR to come from PharmaGap in a long time. It essentially, and for the first time, tells us what the end game is.
We can now see the individual activities (OHRI, Sloan Kettering, and possibly others unannounced) as parts of the whole, rather than isolated efforts. And the confirmed relationship with NCI is probably the strongest rock they could hope to build around.
The NR portrayed a sense of confidence, and , if anything, was understated. No need for superlatives such as "compelling", etc.
I expect that GAP's plan is to "fly under the radar" for the rest of the year, while they execute their plan. News releases will be minimal (only as required by IROC): the share price will be kept in check, to facilitate PPs as needed to fund the program. But I have no doubt but that the eventual ROI will be worth the wait.
Expect to see the shorts abandon this one in the near future, with some corresponding good buy opportunities.
The shareholder base will then be dominated by longs, which should see the SP move upward later in the year. A licencing deal could certainly cause a pop, but I get a sense from the NR that GAP are more than willing to "go it alone".